LONG-TERM COST-EFFECTIVENESS OF ESKETAMINE FOR THE TREATMENT OF TREATMENT-RESISTANT DEPRESSION

被引：0
|
作者：
Touchette, D. [1 ]
Boyer, N. [2 ]
Atlas, S. J. [3 ]
Agboola, F. O. [4 ]
Talon, B. [1 ]
Schultz, B. [1 ]
Kumar, V. M. [4 ]
Fazioli, K. [4 ]
Fluetsch, N. [4 ]
Rind, D. [4 ]
机构：
[1] Univ Illinois, Coll Pharm, Chicago, IL USA
[2] Univ Chicago Hosp Med, Chicago, IL USA
[3] Massachusetts Gen Hosp, Div Gen Internal Med, Boston, MA 02114 USA
[4] Inst Clin & Econ Review, Boston, MA USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMH16
引用
收藏
页码：S683 / S683
页数：1
相关论文
共 50 条
  • [21] Long-Term Treatment With Esketamine Nasal Spray in Patients With Treatment-Resistant Depression: Final Results of the SUSTAIN-3 Study
    Fu, Dong-Jing
    NEUROPSYCHOPHARMACOLOGY, 2023, 48 : 17 - 17
  • [22] COST-EFFECTIVENESS OF VAGUS NERVE STIMULATION FOR TREATMENT-RESISTANT DEPRESSION IN THE UNITED KINGDOM
    Sawyer, L.
    Gentilini, A.
    Salih, F.
    Langford, B.
    Barion, F.
    Murphy, J.
    VALUE IN HEALTH, 2020, 23 : S587 - S587
  • [23] LONG-TERM OUTCOME OF TREATMENT-RESISTANT DEPRESSION IN OLDER ADULTS
    STOUDEMIRE, A
    HILL, CD
    MORRIS, R
    LEWISON, BJ
    AMERICAN JOURNAL OF PSYCHIATRY, 1993, 150 (10): : 1539 - 1540
  • [24] Long-Term Impact of Residual Symptoms in Treatment-Resistant Depression
    Fekadu, Abebaw
    Wooderson, Sarah C.
    Rane, Lena J.
    Markopoulou, Kalypso
    Poon, Lucia
    Cleare, Anthony J.
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2011, 56 (09): : 549 - 557
  • [25] Comparing the Effectiveness of IV Ketamine and Esketamine in a Group of Outpatients with Treatment-Resistant Depression
    Keshishyan, Anahit
    Silbersweig, Arielle
    Kim, Jonathan
    Coolidge, Sarah J.
    Tsygankova, Valeriya
    Celedon-Garcia, Rafael D.
    Richardon, Gabriel S.
    McDonald, William M.
    Kitay, Brandon M.
    Posse, Patricio Riva
    Hershenberg, Rachel
    Chatham, Anthony
    Hutchison, Charles
    Hermida, Adriana P.
    JOURNAL OF ECT, 2024, 40 (03) : E22 - E22
  • [26] Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
    Rognoni, Carla
    Falivena, Camilla
    Costa, Francesco
    Armeni, Patrizio
    PHARMACOECONOMICS, 2023, 41 (2) : 209 - 225
  • [27] Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
    Carla Rognoni
    Camilla Falivena
    Francesco Costa
    Patrizio Armeni
    PharmacoEconomics, 2023, 41 : 209 - 225
  • [28] Long-term safety of ketamine and esketamine in treatment of depression
    Nikayin, Sina
    Murphy, Eva
    Krystal, John H.
    Wilkinson, Samuel T.
    EXPERT OPINION ON DRUG SAFETY, 2022, 21 (06) : 777 - 787
  • [29] Esketamine Combined With SSRI or SNRI for Treatment-Resistant Depression
    Del Casale, Antonio
    Spirito, Sara
    Arena, Jan Francesco
    Preissner, Saskia
    Borro, Marina
    Gentile, Giovanna
    Modesti, Martina Nicole
    Preissner, Robert
    Ferracuti, Stefano
    Simmaco, Maurizio
    JAMA PSYCHIATRY, 2025,
  • [30] How effective are ketamine or esketamine in treatment-resistant depression?
    Veluri, N.
    Mansuri, Z.
    EUROPEAN PSYCHIATRY, 2021, 64 : S330 - S330
12345